Phase 3 Trial of Fintepla (fenfluramine oral solution) for the treatment of Lennox-Gastaut Syndrome meets primary endpoint

Trial in 263 subjects with this severe and treatment-resistant childhood-onset epilepsy met its primary endpoint of showing a statistically significant reduction from baseline compared to placebo in median percent change in monthly drop seizure frequency (26.5% vs, 7.8%;p=0.0012)


Biospace Inc.